STATE-OF-THE-ART PAPER
Evaluation and Management of the Cardiac Amyloidosis
Joseph B. Selvanayagam, FRACP, DPhil*, ,*,
Philip N. Hawkins, PhD, FRCP, FRCPath ,
Biju Paul, MBBS,
Saul G. Myerson, MD, MRCP* and
Stefan Neubauer, MD, FRCP*
* Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, London, United Kingdom
Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, Australia.
Manuscript received January 3, 2007;
revised manuscript received August 27, 2007,
accepted August 28, 2007.
* Reprint requests and correspondence: Dr. Joseph B. Selvanayagam, Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide 5042, Australia. (Email: joseph.selva{at}fmc.sa.gov.au).
Cardiac amyloidosis describes clinically significant involvement of the heart by amyloid deposition, which may or may not be associated with involvement of other organs. The purpose of this review is to summarize the current state of evidence for the effective evaluation and management of cardiac amyloidosis. Acquired systemic amyloidosis occurs in more than 10 per million person-years in the U.S. population. Although no single noninvasive test or abnormality is pathognomonic of cardiac amyloid, case-control studies indicate that echocardiographic evidence of left ventricular wall thickening, biatrial enlargement, and increased echogenicity in conjunction with reduced electrocardiographic voltages is strongly suggestive of cardiac amyloidosis. Furthermore, newer echocardiographic techniques such as strain and strain rate imaging can demonstrate impairment in longitudinal function before ejection fraction becomes abnormal. Recent observational studies also suggest that cardiovascular magnetic resonance imaging yields characteristic findings in amyloidosis, offering promise for the early detection of cardiac involvement, and the presence of detectable cardiac troponin and elevated B-type natriuretic peptide in serum of affected patients portends an adverse prognosis. Management strategies for cardiac amyloid are largely based on nonrandomized single-center studies. One of the few published randomized studies shows the superiority of oral prednisolone and melphalan compared with colchicine in systemic AL amyloidosis. Intermediate-dose infusional chemotherapy regimes (such as vincristine, adriamycin, and dexamethasone) and high-dose chemotherapy with peripheral stem cell rescue have been used widely, but treatment-related mortality remains substantial with chemotherapy. Recent studies also indicate promising strategies to stabilize the native structures of amyloidogenic proteins; inhibit fibril formation; and disrupt established deposits using antibodies, synthetic peptides, and small-molecule drugs.
|
Abbreviations and Acronyms
| | CMR = cardiovascular magnetic resonance imaging | | ECG = electrocardiogram/electrocardiographic | | LV = left ventricular | | SAA = serum amyloid A protein | | SAP = serum amyloid P component | | SSA = senile systemic amyloidosis | | TTR = transthyretin |
|
This article has been cited by other articles:
|
|
|
|
 
P. T. Sattianayagam, A. F. Hahn, C. J. Whelan, S. D. J. Gibbs, J. H. Pinney, A. J. Stangou, D. Rowczenio, P. W. Pflugfelder, Z. Fox, H. J. Lachmann, et al.
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant
Eur. Heart J.,
January 6, 2012;
(2012)
ehr383v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rapezzi, C. C. Quarta, P. L. Guidalotti, C. Pettinato, S. Fanti, O. Leone, A. Ferlini, S. Longhi, M. Lorenzini, L. B. Reggiani, et al.
Role of 99mTc-DPD Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis
J. Am. Coll. Cardiol. Img.,
June 1, 2011;
4(6):
659 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Dubrey, P. N. Hawkins, and R. H. Falk
Amyloid diseases of the heart: assessment, diagnosis, and referral
Heart,
January 1, 2011;
97(1):
75 - 84.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Y. H. Lip, H.-F. Tse, and A. J. Stewart Coats
Restrictive and infiltrative cardiomyopathies
ODR Cardiology,
January 1, 2011;
1(1):
med-9780199568093-div1-00 - med-9780199568093-div1-00.
[Full Text]
|
|
|
|
|
|
|
J. B. Selvanayagam and D. P. Leong
MR Imaging and Cardiac Amyloidosis: Where to Go From Here?
J. Am. Coll. Cardiol. Img.,
February 1, 2010;
3(2):
165 - 167.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Myerson, J. Francis, and S. Neubauer
Cardiac amyloidosis
OSH Cardiovascular Magnetic Resonance,
January 1, 2010;
1(1):
med-9780199549573-div1-08 - med-9780199549573-div1-08.
[Full Text]
|
|
|
|
|
|
|
B. A. Austin, W.H. W. Tang, E. R. Rodriguez, C. Tan, S. D. Flamm, D. O. Taylor, R. C. Starling, and M. Y. Desai
Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis
J. Am. Coll. Cardiol. Img.,
December 1, 2009;
2(12):
1369 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Kelley, J. L. Januzzi, and R. H. Christenson
Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure
Clin. Chem.,
December 1, 2009;
55(12):
2098 - 2112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Karamitsos, J. M. Francis, S. Myerson, J. B. Selvanayagam, and S. Neubauer
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1407 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Sparrow, N. Merchant, Y. L. Provost, D. J. Doyle, E. T. Nguyen, and N. S. Paul
CT and MR Imaging Findings in Patients with Acquired Heart Disease at Risk for Sudden Cardiac Death1
RadioGraphics,
May 1, 2009;
29(3):
805 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam
Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Circ Heart Fail,
November 1, 2008;
1(4):
249 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Leone, G. Boriani, G. Marinelli, and C. Rapezzi
Local Amyloidosis as a Possible Component of the Atrial Remodeling Accompanying Trial
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2444 - 2445.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rapezzi, P. Guidalotti, F. Salvi, L. Riva, and E. Perugini
Usefulness of 99mTc-DPD Scintigraphy in Cardiac Amyloidosis
J. Am. Coll. Cardiol.,
April 15, 2008;
51(15):
1509 - 1510.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Selvanayagam, P. N. Hawkins, and S. Neubauer
Reply
J. Am. Coll. Cardiol.,
April 15, 2008;
51(15):
1510 - 1510.
[Full Text]
[PDF]
|
|
|
|
